A Phase 1b Open Label Multicentre Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers

PURPOSE: Squamous cell lung cancers (SQCLC) account for 25% of all NSCLCs, yet the prognosis of these patients is poor and treatment options are limited. Amplified FGFR1 is one of the most common oncogenic events in SQCLCs, occurring in ~20% of cases. AZD4547 is a potent and selective FGFR1-3 inhibi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Paik, Paul K., Shen, Ronglai, Berger, Michael F., Ferry, David, Soria, Jean-Charles, Mathewson, Alastair, Rooney, Claire, Smith, Neil R., Cullberg, Marie, Kilgour, Elaine, Landers, Donal, Frewer, Paul, Brooks, Nigel, Andre, Fabrice
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600836/
https://ncbi.nlm.nih.gov/pubmed/28615371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0645
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados